Founded by a team that includes business leaders, physicians and reproductive-science specialists, Incintas Therapeutics focuses on a stubborn problem in assisted reproduction: embryos that fail to implant. The company is developing a localized, time-released progesterone therapy for fertility-treatment patients, intended to extend the uterus’s brief period of receptivity.